期刊文献+

他汀类降血脂药匹他伐他汀钙 被引量:4

下载PDF
导出
摘要 目的:介绍一种新的他汀类降血脂药物匹他伐他汀钙,为其临床应用提供参考。方法:查阅文献资料,综述匹他伐他汀钙的药理毒理作用临床研究进展。结果:匹他伐他汀钙是强效的HMG-CoA还原酶抑制剂,具有显著降低密度脂蛋白胆固醇(LDL-C)和甘油三酯(TG),升高高密度脂蛋白胆固醇(HDL-C)的作用,其药代动力学特征优良,毒性低,安全性和耐受性良好。结论:匹他伐他汀钙是理想的调血脂药,值得临床应用推广。
作者 竺平晖
出处 《中国药业》 CAS 2003年第5期77-79,共3页 China Pharmaceuticals
  • 相关文献

参考文献11

  • 1Nakagawa S, Tanabe S, Tamaki T, et al. Effect of NK - 104, an HMG -CoA reductase inhibitor on lipid metabolism in HepG2 cells[J]. Jpn Pharmacol Ther, 2001,29(1 ): 51 -56.
  • 2Aoki T, Yamazaki H, Suzuki H, et al. Cholesterol - lowering effect of NK -104, a 3 - hydroxy - 3 - methylglutaryl - coenzyme A reductase in hibitor, inguinea pig model of hyperlipidemia [ J ]. Arzneimittelforschung, 2001, 51 (3):197 - 203.
  • 3Suzuki H, Yamazaki H, Aoki T, et al. Hypolipidemic effect of NK - 104 and other 3- hydroxy- 3- methylglutaryl coenzyme A reductase in hibitors inguinea pigs [J]. Arzneimittelforschung, 2001, 51 ( 1 ) : 38 - 45.
  • 4Suzuki H, Yamazaki H, Aoki T, et al. Lipid - lowering and antiatherosclerotic effect of NK - 104, a potent 3 - hydroxy - 3 - methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits[J].Arzneimittelforschung, 2000, 50 ( 11 ) : 995 - 1 003.
  • 5Takemoto M, Kitahara M, Yokote K, et al. NK- 104, a 3 -hydroxy -3 -methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells[J]. Br J Pharmacol, 2001, 133 (1):83 -88.
  • 6Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin(NK -104), a new inhibitor of 3 - hydroxy - 3 - methyl - glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans[J].Arzneimittelforschung, 2002, 52 (10) : 745 - 753.
  • 7Akiba T, Shibuta T, Amano Y, et al. 28 - day repeated oral toxicity study of a hypolipidemic agent, NK - 104 in rats[J]. Joxicol Sci, 1998, 23(Suppl, 5):701 -711.
  • 8Akiba T, Shibuta T, Amano Y, et al. six - month repeated oral toxicity study of NK - 104 in rats[J]. Toxicol sci, 1998, 23 (Suppl, 5): 713 -720.
  • 9Saito Y, Yamada N, Teramoto T, et al. A randomized, double - blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia[J]. Atherosclerosis 2002, 162(2):373 -379.
  • 10Teramoto T, Salto Y, Nakaya N, et al. Clinical evaluation of NK- 104(pitavastatin) in long- term treatment of patients with hyperlipidemia[ J ]. Atherosclerosis, 2000, 151 ( 1 ) : 53.

同被引文献61

  • 1何笑荣,邹定,姜文清,马捷,李金娥.降血脂新药匹伐他汀[J].中国新药杂志,2005,14(4):483-487. 被引量:32
  • 2刘华,孟四平,李中原,庞学民.他汀类药物对肝功能影响的研究[J].中国心血管病研究,2006,4(7):523-524. 被引量:9
  • 3张月兰,程颖,李轶男,曾定尹,齐国先.不同剂量匹伐他汀对小鼠缺血肢血流恢复的影响[J].中国医科大学学报,2006,35(3):251-252. 被引量:2
  • 4陈图刚,陈君柱.辛伐他汀对高胆固醇血症患者动脉弹性的影响[J].中国综合临床,2006,22(11):969-970. 被引量:2
  • 5陈巧玲,蔡宝祥.他汀类药物防治动脉粥样硬化作用研究进展[J].药学实践杂志,2006,24(6):321-324. 被引量:4
  • 6Baker W L, Datta R. Pitavastatin: a new 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitor for the treat- ment of hyperlipidemia [ J ]. Adv Ther, 2011,28 ( 1 ) : 13- 27.
  • 7Panchal H J, Suhagia B N, Patel M M, et al. Estimation of pitavastatin calcium in tablet dosage ibrms by column liquid chromatography and ultraviolet spectrophotometry [J].J AOAC Int, 2009,92(1):158-164.
  • 8Suzuki M, Iwasaki H, Fujikawa Y, et al. Synthesis and biological evaluations of quinoline-based HMG-CoA re- ductase inhibitors [ J ]. Bioorg Med Chem, 2001,9 ( 10 ) : 2727 -2743.
  • 9Saito Y. Critical appraisal of the role of pitavastatin in trea- ting dyslipidemias and achieving lipid goals [ J ]- Vase Health Risk Manag, 2009,5:921-936.
  • 10Park S, Kang H J, Rim S J, et al. A randomized, open- label study to evaluate the efficacy and safety of pitavasta- tin compared with simvastatin in Korean patients with hy- percholesterolemia[ J ]. Clin Ther, 2005,27 ( 7 ) : 1074- 1082.

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部